Fibrocytes contribute to mesenteric manifestations in Crohn’s disease.

Author(s)
M.G. Kiernan¹, S.M. Sahebally¹,², A. Jarrar³, J.P. Burke⁴,⁵, J. Hogan², P.A. Kiely⁶, B. Shen³,⁷, M. Moloney⁸, M. Skelly⁸, D. Leddin², H. Hedaya², P.N. Faul¹⁰, V. Healy¹⁰, P.R. O’Connell¹⁸, S. Martin⁵, F. Shanahan, C. Dunne¹, J.C. Coffey¹,²

Institute(s)/Affiliation(s)
¹ Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation and Immunity (4i), University of Limerick, Limerick, Ireland
² Department of Surgery, University Hospital Limerick, Limerick, Ireland
³ The Lerner College of Medicine, the Cleveland Clinic Foundation, Cleveland, Ohio, USA
⁴ School of Medicine and Medical Sciences, University College Dublin, Ireland
⁵ Centre for Colorectal Disease, St. Vincent’s University Hospital, Dublin, Ireland
⁶ Department of Life Sciences, Materials and Surface Science Institute and Stokes Institute, University of Limerick, Limerick, Ireland
⁷ Departments of Gastroenterology/Hepatology, the Cleveland Clinic Foundation, Cleveland, Ohio, USA
⁸ Department of Gastroenterology, University Hospital Limerick, Limerick, Ireland
⁹ Department of Medicine, Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, Nova Scotia
¹⁰ Department of Pathology, University Hospital Limerick, Limerick, Ireland
¹¹ Department of Medicine, Alimentary Pharmabiotic Centre (APC) Microbiome Institute, University College Cork, Cork, Ireland

Email
Miranda.Kiernan@ul.ie
Fibrocytes are a precursor cell type, which can differentiate into fibroblasts or adipocytes (1). The mesentery in Crohn’s disease, frequently displays disease manifestations such as mesenteric thickening and fat wrapping. This study aimed to investigate the contribution of fibrocytes to mesenteric manifestations in Crohn’s disease.

Ethical approval and informed consent were obtained from the HSE Mid-Western Regional Hospital Research Ethics Committee. Mesenteric disease was graded based on presence and extent of factors listed in Table 1. Circulating and mesenteric fibrocytes were identified and enumerated by flow cytometric and immunohistochemical analysis. Relationships between these mesenteric and systemic manifestations were determined. Data are presented as mean ± standard error. Statistical analyses were performed in SPSSv22.

Circulating fibrocytes were significantly elevated in Crohn’s disease (n=25) when compared to healthy controls (n=11) (independent t-test: 7.7 ± 0.97% vs. 2.1 ± 0.34%; p<0.001). Furthermore, Crohn’s disease mesentery displayed a higher number of myofibrocytes than normal tissue. Mesenteric disease activity index directly correlated with the systemic disease manifestations (Pearson’s correlation coefficient: r=0.80; p<0.05).

The increase in fibrocytes is directly related to the extent of mesenteric disease.

Table 1: Scoring system for mesenteric disease manifestations.

<table>
<thead>
<tr>
<th>Description</th>
<th>Severity</th>
<th>Grade</th>
<th>Stage</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>FW minimal, MT minimal</td>
<td>Early</td>
<td>Mild</td>
<td>One</td>
<td>1</td>
</tr>
<tr>
<td>FW &lt;25%, MT adipovascular pedicle only</td>
<td>Intermediate I</td>
<td>Moderate</td>
<td>Two A</td>
<td>2</td>
</tr>
<tr>
<td>FW &lt;25%, pan-mesenteric MT</td>
<td>Intermediate II</td>
<td>Moderate</td>
<td>Two B</td>
<td>4</td>
</tr>
<tr>
<td>FW &gt;25%, pan-mesenteric MT</td>
<td>Advanced</td>
<td>Severe</td>
<td>Three</td>
<td>6</td>
</tr>
</tbody>
</table>

References
Conflict of interest
The authors declare that they have no affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Disclosures
The authors have nothing to disclose.